Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 10, 2015; 6(5): 744-751
Published online Jun 10, 2015. doi: 10.4239/wjd.v6.i5.744
Emerging links between type 2 diabetes and Alzheimer’s disease
Gumpeny R Sridhar, Gumpeny Lakshmi, Gumpeny Nagamani
Gumpeny R Sridhar, Gumpeny Lakshmi, Gumpeny Nagamani, Endocrine and Diabetes Centre, Department of Obstetrics and Gynecology, Andhra Medical College, Visakhapatnam 530002, India
Author contributions: Sridhar GR, Lakshmi G and Nagamani G contributed equally to this paper.
Conflict-of-interest: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Gumpeny R Sridhar, MD, DM, FACE, FRCP, Endocrine and Diabetes Centre, Department of Obstetrics and Gynecology, Andhra Medical College, 15-12-15 Krishnanagar, Visakhapatnam 530002, India. sridharvizag@gmail.com
Telephone: +91-891-2566301 Fax: +91-891-2509427
Received: August 29, 2014
Peer-review started: August 30, 2014
First decision: November 27, 2014
Revised: December 4, 2014
Accepted: March 16, 2015
Article in press: March 18, 2015
Published online: June 10, 2015
Processing time: 294 Days and 17.9 Hours
Abstract

Type 2 diabetes mellitus and Alzheimer’s disease are both associated with increasing age, and each increases the risk of development of the other. Epidemiological, clinical, biochemical and imaging studies have shown that elevated glucose levels and diabetes are associated with cognitive dysfunction, the most prevalent cause of which is Alzheimer’s disease. Cross sectional studies have clearly shown such an association, whereas longitudinal studies are equivocal, reflecting the many complex ways in which the two interact. Despite the dichotomy, common risk and etiological factors (obesity, dyslipidemia, insulin resistance, and sedentary habits) are recognized; correction of these by lifestyle changes and pharmacological agents can be expected to prevent or retard the progression of both diseases. Common pathogenic factors in both conditions span a broad sweep including chronic hyperglycemia per se, hyperinsulinemia, insulin resistance, acute hypoglycemic episodes, especially in the elderly, microvascular disease, fibrillar deposits (in brain in Alzheimer’s disease and in pancreas in type 2 diabetes), altered insulin processing, inflammation, obesity, dyslipidemia, altered levels of insulin like growth factor and occurrence of variant forms of the protein butyrylcholinesterase. Of interest not only do lifestyle measures have a protective effect against the development of cognitive impairment due to Alzheimer’s disease, but so do some of the pharmacological agents used in the treatment of diabetes such as insulin (especially when delivered intranasally), metformin, peroxisome proliferator-activated receptors γ agonists, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes must be recognized as a risk for development of Alzheimer’s disease; clinicians must ensure preventive care be given to control and postpone both conditions, and to identify cognitive impairment early to manage it appropriately.

Keywords: Cognition; Insulin resistance; Insulin; Butyrylcholinesterase; Dementia

Core tip: Type 2 diabetes mellitus is a risk factor for future development of Alzheimer’s disease, the most prominent cause of cognitive failure in the elderly. Common pathogenic mechanisms underpin both conditions. Therapeutic strategies in prevention (lifestyle changes) and pharmacological agents (biguanides, intranasal insulin, thiazolidinediones, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors could also be useful against Alzheimer’s disease.